# BYLieve (NCT03056755)

> Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03056755
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Breast Cancer
- Interventions: Alpelisib; Fulvestrant; Letrozole; Goserelin; Leuprolide
- Enrollment: 383
- Primary outcome: Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months

## Commentary we found

- YouTube: 9
- Podcasts: 9
- X threads: 8

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=bylieve-nct03056755

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03056755", "email": "<work email>"}; the inbox owner confirms by the emailed link.